Literature DB >> 28693371

Who is 'Molly'? MDMA adulterants by product name and the impact of harm-reduction services at raves.

Sarah Saleemi1, Steven J Pennybaker1, Missi Wooldridge2, Matthew W Johnson3.   

Abstract

Methylenedioxymethamphetamine (MDMA), often sold as 'Ecstasy' or 'Molly', is commonly used at music festivals and reported to be responsible for an increase in deaths over the last decade. Ecstasy is often adulterated and contains compounds that increase morbidity and mortality. While users and clinicians commonly assume that products sold as Molly are less-adulterated MDMA products, this has not been tested. Additionally, while pill-testing services are sometimes available at raves, the assumption that these services decrease risky drug use has not been studied. This study analyzed data collected by the pill-testing organization, DanceSafe, from events across the United States from 2010 to 2015. Colorimetric reagent assays identified MDMA in only 60% of the 529 samples collected. No significant difference in the percentage of samples testing positive for MDMA was determined between Ecstasy and Molly. Individuals were significantly less likely to report intent to use a product if testing did not identify MDMA (relative risk (RR) = 0.56, p = 0.01). Results suggest that Molly is not a less-adulterated substance, and that pill-testing services are a legitimate harm-reduction service that decreases intent to consume potentially dangerous substances and may warrant consideration by legislators for legal protection. Future research should further examine the direct effects of pill-testing services and include more extensive pill-testing methods.

Entities:  

Keywords:  Ecstasy; MDMA; Molly; harm reduction; pill testing

Mesh:

Substances:

Year:  2017        PMID: 28693371     DOI: 10.1177/0269881117715596

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  18 in total

Review 1.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

2.  City checking: Piloting the UK's first community-based drug safety testing (drug checking) service in 2 city centres.

Authors:  Fiona Measham
Journal:  Br J Clin Pharmacol       Date:  2020-02-17       Impact factor: 4.335

Review 3.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

4.  "Ecstasy" to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA.

Authors:  Sean B Dolan; Zhenglan Chen; Renqi Huang; Michael B Gatch
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

5.  The drug purity discounting task: Ecstasy use likelihood is reduced by probabilistic impurity according to harmfulness of adulterants.

Authors:  Sean B Dolan; Matthew W Johnson
Journal:  Drug Alcohol Depend       Date:  2020-01-20       Impact factor: 4.492

6.  Willingness to provide a hair sample for drug testing among electronic dance music party attendees.

Authors:  Joseph J Palamar; Alberto Salomone; Charles M Cleland; Scott Sherman
Journal:  Subst Abus       Date:  2018-08-17       Impact factor: 3.716

Review 7.  Synthetic cathinone adulteration of illegal drugs.

Authors:  Chicora F Oliver; Joseph J Palamar; Alberto Salomone; Steven J Simmons; Helene L Philogene-Khalid; Nick Stokes-McCloskey; Scott M Rawls
Journal:  Psychopharmacology (Berl)       Date:  2018-10-18       Impact factor: 4.530

8.  Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats.

Authors:  Quenten Highgate; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2018-09-12       Impact factor: 4.530

9.  Self-reported Subjective Effects of Analytically Confirmed New Psychoactive Substances Consumed by e-Psychonauts: Protocol for a Longitudinal Study Using a New Internet-Based Methodology.

Authors:  Marc Grifell; Guillem Mir Fuster; Mireia Ventura Vilamala; Liliana Galindo Guarín; Xoán Carbón Mallol; Carl L Hart; Víctor Pérez Sola; Francesc Colom Victoriano
Journal:  JMIR Res Protoc       Date:  2021-07-02

10.  Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.

Authors:  Isaac V Cohen; Tigran Makunts; Ruben Abagyan; Kelan Thomas
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.